Literature DB >> 18456393

11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.

Riccardo Schiavina1, Vincenzo Scattoni, Paolo Castellucci, Maria Picchio, Barbara Corti, Alberto Briganti, Alessandro Franceschelli, Francesco Sanguedolce, Alessandro Bertaccini, Moshen Farsad, Giampiero Giovacchini, Stefano Fanti, Walter Franco Grigioni, Ferruccio Fazio, Francesco Montorsi, Patrizio Rigatti, Giuseppe Martorana.   

Abstract

BACKGROUND: Conventional imaging (CI) techniques are inadequate for lymph node (LN) staging in prostate cancer (PCa).
OBJECTIVES: To assess the accuracy of (11)C-Choline positron emission tomography/computerized tomography (PET/CT) for LN staging in intermediate-risk and high-risk PCa and to compare it with two currently used nomograms. DESIGN, SETTING, AND PARTICIPANTS: From January 2007 to September 2007, 57 PCa patients at intermediate risk (n=27) or high risk (n=30) were enrolled at two academic centres. All patients underwent preoperative PET/CT and radical prostatectomy with extended pelvic LN dissection (PLND). Risk of LN metastasis (LNM) was assessed using available nomograms. MEASUREMENTS: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and number of correctly recognized cases for LNM detection at PET/CT were assessed. The accuracy of PET/CT for LNM detection was compared with the accuracy of nomograms for LNM prediction by using receiver operating characteristic (ROC) analysis. RESULTS AND LIMITATIONS: Fifteen patients (26%) had LNMs, and a total of 41 LNMs were identified. On a patient analysis, sensitivity, specificity, PPV, NPV, and number of correctly recognized cases at PET/CT were 60.0%, 97.6%, 90.0%, 87.2%, and 87.7% while, on node analysis, these numbers were 41.4%, 99.8%, 94.4%, 97.2%, and 97.1%. The mean diameter (in mm) of the metastatic deposit of true-positive LNs was significantly higher than that of false-negative LNs (9.2 vs 4.2; p=0.001). PET/CT showed higher specificity and accuracy than the nomograms; however, in pairwise comparison, the areas under the curve (AUCs) were not statistically different (all p values >0.05).
CONCLUSIONS: In patients with intermediate-risk and high-risk PCa, (11)C-Choline PET/CT has quite a low sensitivity for LNM detection but performed better than clinical nomograms, with equal sensitivity and better specificity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456393     DOI: 10.1016/j.eururo.2008.04.030

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  64 in total

Review 1.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

Review 2.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 3.  [Impact of nuclear medicine imaging techniques for lymph node surgery].

Authors:  L S Freudenberg; G Holl; S P Müller; S J Rosenbaum-Krumme; J Sciuk; A Bockisch
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

Review 4.  Beyond haematuria in uro oncology: imaging biomarkers lag behind needs.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01       Impact factor: 9.236

5.  Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.

Authors:  Michael Souvatzoglou; Matthias Eiber; Toshiki Takei; Sebastian Fürst; Tobias Maurer; Florian Gaertner; Hans Geinitz; Alexander Drzezga; Sibylle Ziegler; Stephan G Nekolla; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-02       Impact factor: 9.236

Review 6.  Individualized image-based lymph node irradiation for prostate cancer.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Marco van Vulpen; J Alfred Witjes; Wim J G Oyen; Jelle O Barentsz; Johannes H A M Kaanders
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

7.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

Review 8.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

Review 9.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

Review 10.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.